Table 3 Demographics and baseline clinical characteristics of the AS patients
Baseline characteristics | Overall n = 611 | Responder n = 396 | Non-responder n = 215 | p-value |
|---|---|---|---|---|
Sex (male, %) | 456 (74.6) | 301 (76.0) | 155 (72.1) | 0.334 |
Age at baseline (years) | 38.76 (13.29) | 37.88 (12.85) | 40.38 (13.95) | 0.026 |
Disease duration (years) | 3.56 (5.23) | 3.43 (4.99) | 3.80 (5.63) | 0.405 |
Height (cm) | 169.24 (8.46) | 169.95 (8.37) | 167.93 (8.47) | 0.005 |
Weight (kg) | 67.36 (12.65) | 67.93 (12.62) | 66.30 (12.67) | 0.129 |
Peripheral arthritis (%) | 234 (38.3) | 155 (39.1) | 79 (36.7) | 0.621 |
Enthesitis (%) | 120 (19.6) | 84 (21.2) | 36 (16.7) | 0.222 |
Uveitis (%) | 118 (19.3) | 72 (18.2) | 46 (21.4) | 0.393 |
Dactylitis (%) | 15 (2.5) | 10 (2.5) | 5 (2.3) | 1.000 |
Psoriasis (%) | 16 (2.6) | 8 (2.0) | 8 (3.7) | 0.321 |
Inflammatory bowel disease (%) | 8 (1.3) | 6 (1.5) | 2 (0.9) | 0.814 |
Smoking | ||||
 Smoker + ex-smoker | 179 (45.2) | 284 (46.5) | 105 (48.8) | 0.438 |
 Non-smoker | 217 (54.8) | 327 (53.5) | 110 (51.2) | |
BASDAI | 6.52 (1.70) | 6.75 (1.61) | 6.08 (1.77) | <0.001 |
BASFI | 4.11 (2.53) | 4.47 (2.47) | 3.45 (2.51) | <0.001 |
ESR (mm/h) | 39.77 (30.89) | 42.46 (31.26) | 34.82 (29.64) | 0.003 |
CRP (mg/dL) | 2.52 (3.12) | 2.77 (3.32) | 2.06 (2.64) | 0.007 |
HTN (%) | 96 (15.7) | 48 (12.1) | 48 (22.3) | 0.001 |
DM (%) | 18 (2.9) | 11 (2.8) | 7 (3.3) | 0.934 |
CKD (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
HLA-B27 positive (%) | 543 (88.9) | 358 (90.4) | 185 (86.0) | 0.133 |
NSAIDs use (%) | 521 (85.3) | 334 (84.3) | 187 (87.0) | 0.449 |
Methotrexate (%) | 44 (7.2) | 23 (5.8) | 21 (9.8) | 0.100 |
Sulfasalazine (%) | 35 (5.7) | 19 (4.8) | 16 (7.4) | 0.246 |
Adalimumab (%) | 253 (41.4) | 165 (41.7) | 88 (40.9) | 0.928 |
Etanercept (%) | 74 (12.1) | 47 (11.9) | 27 (12.6) | 0.905 |
Golimumab (%) | 115 (18.8) | 81 (20.5) | 34 (15.8) | 0.196 |
Infliximab (%) | 169 (27.7) | 103 (26.0) | 66 (30.7) | 0.253 |